Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRE-06: Bupropion for Hypoactive Sexual Desire Disorder in Early-Stage Breast Cancer
NCT07596212Phase 2Not yet recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bupropion in hypoactive sexual desire disorder (HSDD) (4 arms), sponsored by University of Illinois Chicago. Primary endpoint: Tolerance of study drugs at 3 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
bupropion
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT07596212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596212.